Company profile

United Therapeutics Corporation

Pipeline6 assets

TreprostinilTyvaso / Prostacyclin receptor / Small Molecule / Respiratory
Idiopathic Pulmonary Fibrosis (IPF)
RalinepagProstacyclin receptor / Small Molecule / Cardiopulmonary
Pulmonary Arterial Hypertension (PAH)
UKidneyUKidney / Xenotransplantation / Organ Transplantation
End Stage Renal Disease
UThymoKidneyUThymoKidney / Xenotransplantation / Organ Transplantation
End Stage Renal Disease
miroliverELAPmiroliverELAP / Regenerative Medicine / Organ Transplantation
Acute Liver Failure
Centralized Lung Evaluation System (CLES)Ex-vivo Perfusion System / Organ Transplantation
Lung Transplant

Latest news18 items

May 27, 2026

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

May 18, 2026

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

Trial Results • Phase 3ATS Breaking News session Sun, May 17, 2026

May 17, 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

Trial Results • Phase 3ATS 2026 presentation Sun, May 17, 2026

May 15, 2026

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

May 12, 2026

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

May 11, 2026

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Presentation / Abstract • Phase 3

May 6, 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Apr 29, 2026

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

Apr 22, 2026

United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

Apr 20, 2026

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

Presentation / Abstract

Apr 8, 2026

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

Mar 30, 2026

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

Trial Results • Phase 3

Mar 11, 2026

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

Trial Results • Phase 3

Mar 9, 2026

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

Mar 3, 2026

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

Mar 2, 2026

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

Trial Results • Phase 3

Feb 25, 2026

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

United Therapeutics Corporation • Endpoint Arena